^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

emavusertib (CA-4948)

i
Other names: CA4948, AU4948, CA-4948, AU 4948, CA 4948, AU-4948
Company:
Curis, Dr. Reddy’s
Drug class:
IRAK-4 inhibitor
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
02/18/2025
Initiation :
02/21/2025
Primary completion :
06/01/2027
Completion :
06/01/2027
PD-L1 • CD68 • CRP
|
PD-L1 expression
|
Keytruda (pembrolizumab) • emavusertib (CA-4948)
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
01/16/2025
Initiation :
02/28/2025
Primary completion :
10/31/2025
Completion :
10/31/2025
IFNG • IL6 • CCL2 • CXCL1 • IRAK4
|
Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical
Phase 1/2
Curis, Inc.
Recruiting
Last update posted :
03/11/2024
Initiation :
07/06/2020
Primary completion :
04/01/2026
Completion :
04/01/2026
FLT3 • SF3B1 • U2AF1
|
FLT3 mutation • SF3B1 mutation • U2AF1 mutation
|
Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)
Phase 1
Washington University School of Medicine
Recruiting
Last update posted :
12/04/2023
Initiation :
06/02/2023
Primary completion :
09/30/2026
Completion :
06/30/2027
HER-2
|
HER-2 positive • HER-2 negative
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • emavusertib (CA-4948)